PDF(Pubmed)
Abstract：
Background: This study examines the impact of the use of the combination of BeGraft and Solaris stent grafts on the outcomes during the covered endovascular reconstruction of aortic bifurcation (BS-CERAB) technique and extension to the iliac arteries. Methods: Consecutive patients with aortoiliac occlusive disease who underwent endovascular treatment using BS-CERAB between January 2020 and December 2023 were included. Patient demographics, symptoms, lesion characteristics, and procedural and follow-up details were collected and analyzed. Perioperative complications and reinterventions were also identified. Results: A total of 42 patients met the inclusion criteria (32 men, 76.2%, median age 72 years, range 59-85). Indications for treatment were intermittent claudication (42.9%) and critical limb ischemia (57.1%). Procedure success was achieved in all cases. The median patient follow-up time was 14 months (1-36). One patient died at a 10-month follow-up due to lung cancer. The mean pre-operative ABI increased from 0.37 ± 0.19 before intervention to 0.71 ± 1.23 post-operatively at 12 months (p = 0.037). The estimated primary patency rates at 3, 6, and 12 months were 90.5%, 85.7%, and 81.0% and primary assisted patency rates were 90.5%, 90.5%, and 85.7%, respectively. Secondary patency was 95.2% at 3 and 6 months and 90.5% at a 12-month follow-up. Active cancer (p = 0.023, OR 2.12 95%CI 1.14-3.25) was a risk factor for restenosis. Conclusions: This mid-term experience shows that the CERAB technique using the combination of BeGraft and Solaris stents grafts, for the endovascular treatment of severe aortoiliac atherosclerotic disease, may allow an effective reconstruction of the aortic bifurcation and iliac arteries related to high-patency and lower-reintervention rates.
摘要：
背景：本研究探讨了Begraft和Solaris支架移植物的组合使用对主动脉分叉覆膜血管内重建（BS-CERAB）技术和延伸至the动脉的结果的影响。方法：纳入2020年1月至2023年12月间接受BS-CERAB血管内治疗的主动脉髂动脉闭塞性疾病患者。患者人口统计学，症状,病变特征,收集并分析了程序和随访细节.还确定了围手术期并发症和再干预措施。结果:共有42例患者符合纳入标准(32例男性,76.2%,中位年龄72岁，范围59-85）。治疗指征为间歇性跛行(42.9%)和严重肢体缺血(57.1%)。在所有情况下都取得了成功。患者中位随访时间为14个月(1～36个月)。一名患者因肺癌在10个月的随访中死亡。术前平均ABI从干预前的0.37±0.19增加到术后12个月的0.71±1.23(p=0.037)。估计3、6和12个月的主要通畅率为90.5%，85.7%,81.0%，初级辅助通畅率为90.5%，90.5%,和85.7%，分别。随访3个月和6个月时，继发性通畅率为95.2％，12个月时为90.5％。活动性癌症（p=0.023，OR2.1295CI1.14-3.25）是再狭窄的危险因素。结论：中期经验表明，CERAB技术使用Begraft和Solaris支架移植的组合，用于严重主动脉粥样硬化疾病的血管内治疗，可以有效重建与高通畅性和低再介入率相关的主动脉分叉和髂动脉。
